






1a




1b

FIG. 1




2a




2b

Duration of response




2c

Progression-free survival




2d

Overall survival



2e

FIG. 2




*The TMB value of the top 10% of the subjects is 2.9 mutations/Mb

3a

Progression-free survival


	Subjects	Events	Censored	Median PFS
PD-L1>25%	21	14	7	7.2 months
PD-L1≤25%	161	130	31	1.9 months



3b

Overall survival


	Subjects	Events	Censored	Median OS
PD-L1>25%	21	6	15	NE
PD-L1≤25%	161	84	77	15.1 months



3c

Progression-free survival


	Subjects	Events	Censored	Median <u>PFS</u>
<u>TMB</u> high	17	14	3	1.9 months
<u>TMB</u> low	157	123	34	1.9 months



3d

Overall survival

	Subjects	Events	Censored	Median OS
<u>TMB</u> high	17	11	6	9.2 months
<u>TMB</u> low	157	76	81	17.4 months



3e

FIG. 3






FIG. 4




5a



5b

PD (n=80)




5c

FIG. 5

	Number of events/ total number of patients	Median PFS (95% CI) _{mo}	1-year PFS rate (95% CI)%
Toripalimab + chemotherapy	49/146	11.7 (11.0, NE)	49.4 (36.4, 61.1)
Placebo + chemotherapy	79/143	8.0 (7.0, 9.5)	27.9 (18.0, 38.8)


Stratified hazard ratio for progressive disease or death
0.52 (95% CI 0.36-0.74); P=0.0003




Number of people at risk

Toripalimab + chemotherapy	146	125	91	50	17	5	0
Placebo + chemotherapy	143	126	85	32	8	2	0

6a



6b



6c

FIG. 6

	Number of deaths/ total number of patients	Median OS (95% CI) mo	1-year OS rate (95% CI)%	2-year OS rate (95% CI)%
Toripalimab + chemotherapy	25/146	NE (NE, NE)	91.6 (85.6, 95.1)	77.8 (68.0, 85.0)
Placebo + chemotherapy	39/143	NE (22.8, NE)	87.1 (80.4, 91.7)	63.3 (49.8, 74.1)




FIG. 7




FIG. 8